Aberdeen Group
NBIX icon

Aberdeen Group’s Neurocrine Biosciences NBIX Stock Holding History

Aberdeen Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.87M Buy
22,955
+5,655
+33% +$839K 0.01% 717
2026
Q1 		$2.28M Sell
17,300
-22,716
-57% -$3.01M ﹤0.01% 760
2025
Q4 		$5.68M Sell
40,016
-50,029
-56% -$7.25M 0.01% 681
2025
Q3 		$12.6M Sell
90,045
-28,241
-24% -$3.83M 0.02% 561
2025
Q2 		$14.9M Sell
118,286
-102,058
-46% -$11.7M 0.03% 496
2025
Q1 		$24.4M Buy
220,344
+63,770
+41% +$8.08M 0.05% 341
2024
Q4 		$21.4M Buy
156,574
+20,150
+15% +$2.49M 0.04% 357
2024
Q3 		$15.7M Sell
136,424
-24,723
-15% -$3.39M 0.03% 438
2024
Q2 		$22.2M Buy
161,147
+77,935
+94% +$10.7M 0.04% 357
2024
Q1 		$11.5M Sell
83,212
-421
-0.5% -$57.5K 0.02% 525
2023
Q4 		$11M Buy
83,633
+80,420
+2,503% +$9.26M 0.02% 530
2023
Q3 		$361K Sell
3,213
-269
-8% -$28.3K ﹤0.01% 843
2023
Q2 		$328K Buy
3,482
+1,504
+76% +$147K ﹤0.01% 866
2023
Q1 		$200K Buy
+1,978
New +$206K ﹤0.01% 899
2021
Q2 		– Sell
-3,419
Closed -$333K – 1028
2021
Q1 		$333K Buy
3,419
+255
+8% +$26.7K ﹤0.01% 942
2020
Q4 		$303K Buy
3,164
+346
+12% +$33.4K ﹤0.01% 924
2020
Q3 		$271K Sell
2,818
-2,283
-45% -$264K ﹤0.01% 904
2020
Q2 		$622K Sell
5,101
-76,461
-94% -$8.45M ﹤0.01% 837
2020
Q1 		$7.06M Sell
81,562
-695
-0.8% -$68K 0.02% 457
2019
Q4 		$8.84M Buy
82,257
+1,569
+2% +$164K 0.02% 483
2019
Q3 		$7.27M Sell
80,688
-19,608
-20% -$1.83M 0.02% 514
2019
Q2 		$8.47M Sell
100,296
-4,719
-4% -$387K 0.02% 549
2019
Q1 		$9.25M Sell
105,015
-5,565
-5% -$465K 0.02% 524
2018
Q4 		$7.82M Sell
110,580
-26,127
-19% -$2.5M 0.02% 491
2018
Q3 		$16.8M Buy
+136,707
New +$15.5M 0.03% 411

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aberdeen Group's NBIX Position: Q2 2026 in Review

Aberdeen Group increased its Neurocrine Biosciences (NBIX) stake by 33% in Q2 2026, buying an estimated $839K and bringing the position to 22,955 shares worth $3.87M. The position accounts for 0.01% of the portfolio, ranked #717.

Aberdeen Group first reported a position in NBIX in Q3 2018 and has held it in 25 quarters since. The position peaked at $24.4M in Q1 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Aberdeen Group held 22,955 shares of Neurocrine Biosciences worth $3.87M as of Q2 2026.
  • Aberdeen Group bought 5,655 Neurocrine Biosciences shares in Q2 2026, an estimated $839K.
  • Neurocrine Biosciences made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #717 holding.
  • Aberdeen Group first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 25 quarters since.
  • Aberdeen Group's Neurocrine Biosciences position peaked at $24.4M in Q1 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.